OncoMatch/Clinical Trials/NCT03895359
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Is NCT03895359 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Transarterial Chemoembolization for hepatocellular carcinoma.
Treatment: Transarterial Chemoembolization — Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is better for you and your liver cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ZUBROD 0–3
Prior therapy
Cannot have received: radiation therapy
Exception: if would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Lab requirements
Blood counts
ANC ≥ 1,500 cells/mm3; Platelets ≥ 70,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl (transfusion/intervention allowed); Prothrombin time/INR < 2 (if not on anticoagulants)
Liver function
Total bilirubin < 3 mg/dL; Albumin ≥ 28 g/L; AST and ALT < 10 times ULN
CBC, INR, Total bilirubin, albumin, alkaline phosphatase, ALT, AST within 4 weeks prior to study entry. Appropriate levels are as follows: ANC ≥ 1,500 cells/mm3; Platelets ≥ 70,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.); Total bilirubin < 3 mg/dL; Prothrombin time/INR < 2 (if not on anticoagulants); Albumin ≥ 28 g/L; AST and ALT < 10 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify